CWP
CDTX

Clark Wealth Partners’s Cidara Therapeutics CDTX Stock Holding History

Clark Wealth Partners’s Portfolio CDTX Stock Details CDTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-105
Closed -$5.12K – 580
2025
Q2 		$5.12K Buy
+105
New +$2.52K ﹤0.01% 283

Other funds holding CDTX

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
DGM
Darwin Global Management St. Helier, Jersey $3.76B AUM 342.13% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return

Clark Wealth Partners's CDTX Position: Q3 2025 in Review

Clark Wealth Partners sold out of Cidara Therapeutics (CDTX) in Q3 2025, closing a stake of 105 shares — an estimated $5.12K sold.

Clark Wealth Partners first reported a position in CDTX in Q2 2025 and held it in 1 quarter. The position peaked at $5.12K in Q2 2025. 173 funds tracked by Wall St. Rank hold CDTX as of Q3 2025.

  • Clark Wealth Partners reported no remaining Cidara Therapeutics position as of Q3 2025 after selling out during the quarter.
  • Clark Wealth Partners sold 105 Cidara Therapeutics shares in Q3 2025, an estimated $5.12K.
  • Clark Wealth Partners first reported a position in Cidara Therapeutics in Q2 2025 and held it in 1 quarter.
  • Clark Wealth Partners's Cidara Therapeutics position peaked at $5.12K in Q2 2025.
  • 173 funds tracked by Wall St. Rank held Cidara Therapeutics as of Q3 2025.

Based on Clark Wealth Partners's 13F filing for Q3 2025, filed 4 Feb 2026.